To validate HIF-1α as a therapeutic target for a small cell population or an early stage of cancer progression prior to the creation of a hypoxic core, we established in vivo models using a doxycycline-inducible sh-Notch1 U251-MG cell line and chetomin. This evidence concerns the gene HIF1A and cancer.